Ahmed Ghada F, Marino Susan E, Brundage Richard C, Pakhomov Serguei V S, Leppik Ilo E, Cloyd James C, Clark Annie, Birnbaum Angela K
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN, USA.
Br J Clin Pharmacol. 2015 May;79(5):820-30. doi: 10.1111/bcp.12556.
The aim was to develop a quantitative approach that characterizes the magnitude of and variability in phonemic generative fluency scores as measured by the Controlled Oral Word Association (COWA) test in healthy volunteers after administration of an oral and a novel intravenous (IV) formulation of topiramate (TPM).
Nonlinear mixed-effects modelling was used to describe the plasma TPM concentrations resulting from oral or IV administration. A pharmacokinetic-pharmacodynamic (PK-PD) model was developed sequentially to characterize the effect of TPM concentrations on COWA with different distributional assumptions.
Topiramate was rapidly absorbed, with a median time to maximal concentration of 1 h and an oral bioavailability of ~100%. Baseline COWA score increased by an average of 12% after the third administration on drug-free sessions. An exponential model described the decline of COWA scores, which decreased by 14.5% for each 1 mg l(-1) increase in TPM concentration. The COWA scores were described equally well by both continuous normal and Poisson distributions.
This analysis quantified the effect of TPM exposure on generative verbal fluency as measured by COWA. Repetitive administration of COWA resulted in a better performance, possibly due to a learning effect. The model predicts a 27% reduction in the COWA score at the average observed maximal plasma concentration after a 100 mg dose of TPM. The single-dose administration of relatively low TPM doses and narrow range of resultant concentrations in our study were limitations to investigating the PK-PD relationship at higher TPM exposures. Hence, the findings may not be readily generalized to the broader patient population.
本研究旨在开发一种定量方法,以表征在健康志愿者服用托吡酯(TPM)的口服制剂和新型静脉注射(IV)制剂后,通过受控口语单词联想(COWA)测试所测得的音素生成流畅性得分的大小和变异性。
采用非线性混合效应模型来描述口服或静脉注射后血浆TPM浓度。依次建立药代动力学-药效学(PK-PD)模型,以表征在不同分布假设下TPM浓度对COWA的影响。
托吡酯吸收迅速,达到最大浓度的中位时间为1小时,口服生物利用度约为100%。在无药期第三次给药后,基线COWA得分平均提高了12%。指数模型描述了COWA得分的下降情况,TPM浓度每增加1 mg l(-1),COWA得分下降14.5%。连续正态分布和泊松分布对COWA得分的描述效果相当。
该分析量化了TPM暴露对通过COWA测试所测得的生成性言语流畅性的影响。重复进行COWA测试可导致更好的表现,这可能是由于学习效应。该模型预测,在服用100 mg剂量的TPM后,在平均观察到的最大血浆浓度下,COWA得分将降低27%。在我们的研究中,相对较低的TPM剂量单剂量给药以及由此产生的浓度范围较窄,是在更高TPM暴露水平下研究PK-PD关系的局限性。因此,这些发现可能无法轻易推广到更广泛的患者群体。